---

Association of angiotensin converting enzyme gene polymorphism with diabetic nephropathy in patients using lisinopril

---

Original Article

Author Details : Abdur Razaq, Shandana Altaf, Tayyaba Basharat, Shafiq Ahmad Tariq, Sami Siraj, Amer Azhar, Waheed lqbal, Hammad Ullah*, Haroon Khan

Volume : 9, Issue : 2, Year : 2022

Article Page : 96-102

https://doi.org/10.18231/j.ijpp.2022.018

Suggest article by email

Get Permission

---

Abstract

Angiotensin Converting Enzyme (ACE) plays an important role in the development and progression of Diabetic nephropathy (DN). The present study was designed to determine the possible association between ACE gene polymorphism and DN. The study included 242 samples: DN (n = 121), type 2 Diabetes mellitus (DM2) (n = 60) and control (n = 61). The blood samples were collected from the subjects, followed by DNA extraction. Insertion deletion polymorphism of ACE gene studied using specific primers. Patients using Lisinopril were followed for two months. The ACE genotype distribution in DN patients was as follows: DD (n = 47; 38.84%), II (n = 17; 14.04%) and DI (n = 57; 47.10%). In DM group the genotype distribution was DD (n = 4; 6.66%), II (n = 25; 41.66%) and DI (n = 31; 51.66%) while in control group DD (n = 38; 62.29%), II (n = 1; 1.63%) and DI (n = 22; 36.06%). The comparison of II genotype to DD genotype was reflected by p-value =0.0001, OR=17.28 and 95% CI 5.313-49.58. The percent decrease of micro-albuminuria after two months with the use of Lisinopril 10 mg twice a day in DD, II and DI genotype of DN were 31.27%, 12.37% and 16.81%, respectively. Our findings revealed that DD genotype has strong association with DN but not a risk factor for development of disease.

Keywords: Angiotensin-converting enzyme gene, Insertion, Deletion, Diabetic, Inephropathy, lisinopril, Anti­ microalbuminuric effect

How to cite : Razaq A, Altaf S, Basharat T, Tariq S A, Siraj S, Azhar A, Lqbal W, Ullah H, Khan H, Association of angiotensin converting enzyme gene polymorphism with diabetic nephropathy in patients using lisinopril. Indian J Pharm Pharmacol 2022;9(2):96-102

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.